These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
132 related articles for article (PubMed ID: 24027058)
1. Lipids and cognition make good bedfellows for neuroAIDS. Gelbard HA; Gendelman HE Neurology; 2013 Oct; 81(17):1480-1. PubMed ID: 24027058 [No Abstract] [Full Text] [Related]
2. A lipid storage-like disorder contributes to cognitive decline in HIV-infected subjects. Bandaru VV; Mielke MM; Sacktor N; McArthur JC; Grant I; Letendre S; Chang L; Wojna V; Pardo C; Calabresi P; Munsaka S; Haughey NJ Neurology; 2013 Oct; 81(17):1492-9. PubMed ID: 24027056 [TBL] [Abstract][Full Text] [Related]
3. NeuroAIDS in sub-Saharan Africa: a clinical review. Alkali NH; Bwala SA; Nyandaiti YW; Danesi MA Ann Afr Med; 2013; 12(1):1-10. PubMed ID: 23480988 [TBL] [Abstract][Full Text] [Related]
4. Reversible dementia in a patient with central nervous system escape of human immunodeficiency virus. Bogoch II; Davis BT; Venna N J Infect; 2011 Sep; 63(3):236-9. PubMed ID: 21658774 [TBL] [Abstract][Full Text] [Related]
5. Evaluation of HIV RNA and markers of immune activation as predictors of HIV-associated dementia. Sevigny JJ; Albert SM; McDermott MP; McArthur JC; Sacktor N; Conant K; Schifitto G; Selnes OA; Stern Y; McClernon DR; Palumbo D; Kieburtz K; Riggs G; Cohen B; Epstein LG; Marder K Neurology; 2004 Dec; 63(11):2084-90. PubMed ID: 15596754 [TBL] [Abstract][Full Text] [Related]
6. In vivo evidence of HIV-1 productive infection in cerebrospinal fluid of patients with HIV-1 encephalopathy. Di Stefano M; Monno L; Ramon Fiore J; Angarano G AIDS; 1997 Apr; 11(5):698-9. PubMed ID: 9108963 [No Abstract] [Full Text] [Related]
7. An emerging severe leukoencephalopathy: is it due to HIV disease or highly active antiretroviral therapy? Rackstraw S; Meadway J; Bingham J; Al-Sarraj S; Everall I Int J STD AIDS; 2006 Mar; 17(3):205-7. PubMed ID: 16510013 [TBL] [Abstract][Full Text] [Related]
8. Impact of current antiretroviral therapies on neuroAIDS. Vivithanaporn P; Gill MJ; Power C Expert Rev Anti Infect Ther; 2011 Apr; 9(4):371-4. PubMed ID: 21504390 [No Abstract] [Full Text] [Related]
9. Global Perspective of Novel Therapeutic Strategies for the Management of NeuroAIDS. Kumar S; Maurya VK; Dandu HR; Bhatt ML; Saxena SK Biomol Concepts; 2018 May; 9(1):33-42. PubMed ID: 29742062 [TBL] [Abstract][Full Text] [Related]
10. CSF quinolinic acid levels are determined by local HIV infection: cross-sectional analysis and modelling of dynamics following antiretroviral therapy. Valle M; Price RW; Nilsson A; Heyes M; Verotta D Brain; 2004 May; 127(Pt 5):1047-60. PubMed ID: 15013955 [TBL] [Abstract][Full Text] [Related]
11. CSF soluble Fas correlates with the severity of HIV-associated dementia. Towfighi A; Skolasky RL; St Hillaire C; Conant K; McArthur JC Neurology; 2004 Feb; 62(4):654-6. PubMed ID: 14981191 [TBL] [Abstract][Full Text] [Related]
12. Is the glass three-quarters full or one-quarter empty? McArthur JC; Letendre SL J Infect Dis; 2006 Dec; 194(12):1628-31. PubMed ID: 17109332 [No Abstract] [Full Text] [Related]
13. Cerebrospinal fluid ferritin in human immunodeficiency virus infection: a marker of neurologic involvement? Perrella O; Finelli L; Munno I; Perrella A; Soscia E; Carrieri PB J Infect Dis; 1993 Oct; 168(4):1079-80. PubMed ID: 8376826 [No Abstract] [Full Text] [Related]
14. Second assessment of NeuroAIDS in Africa. Robertson K; Kopnisky K; Hakim J; Merry C; Nakasujja N; Hall C; Traore M; Sacktor N; Clifford D; Newton C; Van Rie A; Holding P; Clements J; Zink C; Mielk J; Hosseinipour M; Lalloo U; AMod F; Marra C; Evans S; Liner J; J Neurovirol; 2008 Apr; 14(2):87-101. PubMed ID: 18370346 [TBL] [Abstract][Full Text] [Related]
15. Amplification of human immunodeficiency virus provirus from cerebrospinal fluid: results of long-term clinical follow-up. Shaunak S; Albright RE; Bartlett JA J Infect Dis; 1991 Oct; 164(4):818. PubMed ID: 1894945 [No Abstract] [Full Text] [Related]
16. [NeuroAIDS]. Nakagawa M; Kondo M Nihon Rinsho; 2010 Mar; 68(3):502-7. PubMed ID: 20229798 [TBL] [Abstract][Full Text] [Related]
17. Planning Future Strategies for Domestic and International NeuroAIDS Research, July 24-25, 2008. Joseph J; Clifford D; Douglas SD; Fox H; Gendelman HE; Gonzalez-Scarano F; Grant I; Major E; McArthur J; J Neuroimmune Pharmacol; 2009 Sep; 4(3):283-97. PubMed ID: 19455426 [TBL] [Abstract][Full Text] [Related]
18. Clinical factors related to brain structure in HIV: the CHARTER study. Jernigan TL; Archibald SL; Fennema-Notestine C; Taylor MJ; Theilmann RJ; Julaton MD; Notestine RJ; Wolfson T; Letendre SL; Ellis RJ; Heaton RK; Gamst AC; Franklin DR; Clifford DB; Collier AC; Gelman BB; Marra C; McArthur JC; McCutchan JA; Morgello S; Simpson DM; Grant I; J Neurovirol; 2011 Jun; 17(3):248-57. PubMed ID: 21544705 [TBL] [Abstract][Full Text] [Related]
19. Increased cerebrospinal fluid levels of soluble receptors for tumour necrosis factor in HIV-infected patients with neurological diseases. Vullo V; Mastroianni CM; Lichtner M; Mengoni F; Delia S AIDS; 1995 Sep; 9(9):1099-100. PubMed ID: 8527085 [No Abstract] [Full Text] [Related]
20. AIDS-associated mild neurocognitive impairment is delayed in the era of highly active antiretroviral therapy. Deutsch R; Ellis RJ; McCutchan JA; Marcotte TD; Letendre S; Grant I; AIDS; 2001 Sep; 15(14):1898-9. PubMed ID: 11579260 [No Abstract] [Full Text] [Related] [Next] [New Search]